Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4283402 | 0.99 | KDM1A (0.42) | KDM1ALTA4HKDM4ELIPESMN1; SMN2 | |
| SCHEMBL4301626 | 0.90 | ITGB3 (0.41) | LTA4HKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4972244 | 0.89 | LTA4H (0.47) | KDM1ALTA4HKDM4ELIPESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4289679 | 0.89 | ITGB3 (0.41) | LTA4HKDM4ESMN1; SMN2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL4287144 | 0.85 | HPGD (0.47) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4282373 | 0.84 | L3MBTL1 (0.47) | SMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL4751897 | 0.84 | L3MBTL1 (0.47) | SMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL4293311 | 0.84 | HRH3 (0.43) | LTA4HPARP1 | |
| Hydrochloric Acid SCHEMBL4285610 | 0.83 | L3MBTL1 (0.46) | SMN1; SMN2ALDH1A1PARP1 | |
| Hydrochloric Acid SCHEMBL4286145 | 0.83 | HRH3 (0.42) | LTA4HPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM1A 661/4885LTA4H 1197/4885KDM4E 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.